Angela DeMichele

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile

4.9Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Cancer Cell(2022)10.1016/j.ccell.2022.05.005

Top 4%

4.9DataRank

Top 4%329 citations

Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee +28 more

Papers

Driven by 64 papers — median percentile 96. Top paper: “CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer”.

CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

Nature Medicine(2021)10.1038/s41591-021-01386-7

N/A

13.9DataRank · unranked

521 citations

Nicholas Han, Paul Wileyto, Justin Kim, Sigrid Gouma, James Robinson +55 more

Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer

JAMA Oncology(2020)10.1001/jamaoncol.2020.2535

N/A

6.3DataRank · unranked

225 citations

Angela DeMichele, Christina Yau, Claudine Isaacs, W. Fraser Symmans, Kathy S. Albain +74 more

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Cancer Cell(2022)10.1016/j.ccell.2022.05.005

Top 4%

4.9DataRank

Top 4%329 citations

Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee +28 more

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survival

medRxiv(2020)10.1101/2020.02.03.20019760

N/A

1.6DataRank · unranked

41 citations

Lamorna Brown Swigart, Hsin-Ta Wu, Gillian L. Hirst, Christina Yau, Denise M. Wolf +18 more

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03267-1

N/A

1.4DataRank · unranked

43 citations

Meghna S. Trivedi, Christina Yau, Rita Nanda, Hope S. Rugo, Marie Davidian +55 more

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival

Annals of Oncology(2020)10.1016/j.annonc.2020.11.007

N/A

0.917DataRank · unranked

450 citations

Lamorna Brown Swigart, H.-T. Wu, Gillian L. Hirst, Christina Yau, Denise M. Wolf +19 more

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

npj Breast Cancer(2022)10.1038/s41523-022-00493-z

N/A

0.900DataRank · unranked

27 citations

Andres Forero‐Torres, Douglas Yee, Christina Yau, Denise M. Wolf, John Park +44 more

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Cancer Cell(2021)10.1016/j.ccell.2021.05.009

N/A

0.873DataRank · unranked

337 citations

Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace +40 more

Pulmonary Hypertension and Anastrozole (PHANTOM): A Randomized, Double-Blind, Placebo-Controlled Trial

American Journal of Respiratory and Critical Care Medicine(2024)10.1164/rccm.202402-0371oc

N/A

0.823DataRank · unranked

33 citations

Rui Feng, Susan S. Ellenberg, Roham T. Zamanian, Todd M. Bull, Murali M. Chakinala +15 more

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy

Cancer Cell(2023)10.1016/j.ccell.2023.04.008

N/A

0.777DataRank · unranked

177 citations

Lamorna Brown Swigart, Ziad Ahmed, Rosalyn W. Sayaman, Derrick Renner, Ekaterina Kalashnikova +26 more

Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL

npj Breast Cancer(2020)10.1038/s41523-020-00203-7

N/A

0.666DataRank · unranked

84 citations

David C. Newitt, Jessica Gibbs, Lisa J. Wilmes, Ella F. Jones, Vignesh A. Arasu +57 more

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Nature Communications(2021)10.1038/s41467-021-26019-y

N/A

0.648DataRank · unranked

74 citations

Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, L. J. van ‘t Veer, Douglas Yee +46 more

A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG‐ACRIN Cancer Research Group (EAQ152)

Cancer(2021)10.1002/cncr.34063

N/A

0.616DataRank · unranked

15 citations

Ju‐Whei Lee, Jill B. Gaieski, Shuli Li, Ilana F. Gareen, Keith T. Flaherty +15 more

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2972

N/A

0.612DataRank · unranked

58 citations

Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan +15 more

Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03266-2

N/A

0.610DataRank · unranked

13 citations

Jane Meisel, Christina Yau, Hope S. Rugo, Rita Nanda, Marie Davidian +52 more

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

Annals of Oncology(2021)10.1016/j.annonc.2021.02.011

N/A

0.574DataRank · unranked

45 citations

Christina Yau, Lamorna Brown Swigart, Rebekah Gould, Gregor Krings, Gillian L. Hirst +27 more

Rates of COVID-19–Related Outcomes in Cancer Compared With Noncancer Patients

JNCI Cancer Spectrum(2020)10.1093/jncics/pkaa120

N/A

0.574DataRank · unranked

45 citations

Sanjna Surya, Anh N. Le, Heena Desai, Abigail Doucette, Peter Gabriel +11 more

Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response

Radiology(2021)10.1148/radiol.2021203645

N/A

0.550DataRank · unranked

38 citations

Wen Li, David C. Newitt, Roy Harnish, Fredrik Strand, Alex Nguyen +56 more

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00337-2

N/A

0.510DataRank · unranked

29 citations

Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar +50 more

Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

Annals of Oncology(2024)10.1016/j.annonc.2024.10.018

N/A

0.494DataRank · unranked

26 citations

David S. Wolf, Christina Yau, Lamorna Brown Swigart, Gillian L. Hirst, Claudine Isaacs +15 more

PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies

Breast Cancer Research(2023)10.1186/s13058-022-01559-3

N/A

0.457DataRank · unranked

20 citations

Matt Paul, Christopher J. Sterner, George K. Belka, Dezhen Wang, Peining Xu +8 more

Phase II Study of Palbociclib (PD-0332991) in CCND1 , 2 , or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2150

N/A

0.457DataRank · unranked

20 citations

Fangxin Hong, Richard S. Finn, Angela DeMichele, Edith P. Mitchell, James A. Zwiebel +18 more

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2256

N/A

0.457DataRank · unranked

20 citations

Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien +44 more

ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer

Journal of Clinical Oncology(2024)10.1200/jco.24.00526

N/A

0.442DataRank · unranked

11 citations

Fengmin Zhao, Tarah J. Ballinger, Sofia F. Garcia, Fei Shen, Shamsuddin Virani +19 more

Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.101312

N/A

0.442DataRank · unranked

18 citations

Julia Wulfkuhle, Denise M. Wolf, Lamorna Brown Swigart, Christina Yau, Nicholas O’Grady +22 more

Rates of COVID-19-related Outcomes in Cancer compared to non-Cancer Patients

medRxiv(2020)10.1101/2020.08.14.20174961

N/A

0.425DataRank · unranked

16 citations

Sanjna Surya, Anh N. Le, Heena Desai, Abigail Doucette, Peter Gabriel +11 more

Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.504

N/A

0.416DataRank · unranked

15 citations

Hope S. Rugo, Lajos Pusztai, Rita A. Mukhtar, A. Jo Chien, Christina Yau +7 more

Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2928

N/A

0.406DataRank · unranked

14 citations

Ziad Ahmed, Rosalyn W. Sayaman, Lamorna Brown Swigart, Gillian L. Hirst, Christina Yau +13 more

SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy

JCO Oncology Practice(2021)10.1200/op.21.00113

N/A

0.373DataRank · unranked

3 citations

Sanjna Surya, Noah G. Goodman, Anh N. Le, Gregory Kelly, Olutosin Owoyemi +37 more

Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101799

N/A

0.345DataRank · unranked

9 citations

Denise M. Wolf, Christina Yau, Lamorna Brown Swigart, Julie Wulfkuhle, Isela Gallagher +21 more

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0036

N/A

0.330DataRank · unranked

8 citations

Opeyemi A. Jegede, Mark A. Dickson, Angela DeMichele, Richard Piekarz, Robert J. Gray +15 more

Impact of deformable registration methods for prediction of recurrence free survival response to neoadjuvant chemotherapy in breast cancer: Results from the ISPY 1/ACRIN 6657 trial

Translational Oncology(2022)10.1016/j.tranon.2022.101411

N/A

0.312DataRank · unranked

7 citations

Eric A. Cohen, Nariman Jahani, Susan P. Weinstein, Lauren Pantalone, Nola M. Hylton +5 more

A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.605

N/A

0.312DataRank · unranked

7 citations

Fengmin Zhao, Carlos L. Arteaga, W. Fraser Symmans, Ben Ho Park, Brian L. Burnette +12 more

MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer

Tomography(2025)10.3390/tomography11030026

N/A

0.300DataRank · unranked

4 citations

Natsuko Onishi, Jessica Gibbs, Lisa J. Wilmes, Nu N. Le, Pouya Metanat +12 more

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes

Frontiers in Oncology(2023)10.3389/fonc.2023.1192208

N/A

0.297DataRank · unranked

5 citations

Amrita Basu, Christina Yau, Denise M. Wolf, Hani Goodarzi, Sourav Bandyopadhyay +10 more

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors

Nature Communications(2025)10.1038/s41467-025-65432-5

N/A

0.292DataRank · unranked

6 citations

Nayelis A. Manon, Denise M. Wolf, Samuel Rivero-Hinojosa, Ziad Ahmed, Rosalyn W. Sayaman +20 more

Improved pathologic complete response rates for triple-negative breast cancer in the I-SPY2 Trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.591

N/A

0.292DataRank · unranked

6 citations

Rebecca Shatsky, Christina Yau, Denise M. Wolf, Rita Nanda, L. J. van ‘t Veer +4 more

Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07555-9

N/A

0.255DataRank · unranked

4 citations

Mike Campbell, Christina Yau, A. Jo Chien, Anne M. Wallace, Claudine Isaacs +18 more

Reply to T. Shimoi et al and Y. Shimanuki et al

Journal of Clinical Oncology(2021)10.1200/jco.21.01905

N/A

0.209DataRank · unranked

2 citations

Fengmin Zhao, Carlos L. Arteaga, W. Fraser Symmans, Ben Ho Park, Brian L. Burnette +20 more

A genome-wide association study of breast cancer in women of African ancestry

UNC Libraries(2020)10.17615/f7mx-fb15

N/A

0.208DataRank · unranked

3 citations

Fang Chen, Esther M. John, Stephen J. Chanock, Nancy J. Cox, Julie R. Palmer +27 more

Adjuvant platinum versus capecitabine for residual, invasive, triple‐negative breast cancer: Patient‐reported outcomes in ECOG‐ACRIN EA1131

Cancer(2024)10.1002/cncr.35187

N/A

0.208DataRank · unranked

3 citations

Fengmin Zhao, Ingrid A. Mayer, Amyé Tevaarwerk, Sofia F. Garcia, Carlos L. Arteaga +20 more

355P Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial

Annals of Oncology(2023)10.1016/j.annonc.2023.09.534

N/A

0.165DataRank · unranked

2 citations

Elizabeth Price, Sara J. Venters, Wěi Li, Denise M. Wolf, Jessica Gibbs +14 more

Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.17_suppl.lba520

N/A

0.165DataRank · unranked

2 citations

Kevin Kalinsky, Christina Yau, A. Jo Chien, Judy C. Boughey, Erica Stringer-Reasor +15 more

Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.17_suppl.lba612

N/A

0.165DataRank · unranked

2 citations

Alexandra Thomas, Christina Yau, A. Jo Chien, Carla I. Falkson, Erica Stringer-Reasor +15 more

SARS-CoV-2 seropositivity and seroconversion in patients undergoing active cancer-directed therapy

medRxiv(2021)10.1101/2021.01.15.21249810

N/A

0.104DataRank · unranked

1 citations

Sanjna Surya, Noah Goodman, Anh N. Le, Greg Kelly, Olutosin Owoyemi +37 more

Relative dose intensity and pathologic response rates in HIV-infected and HIV-uninfected breast cancer patients who received neoadjuvant chemotherapy.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e19140

N/A

0.104DataRank · unranked

1 citations

Surbhi Grover, Mohan Narasimhamurthy, Dipho I. Setlhako, Gezahen N Ayane, Tlotlo Ralefala +5 more

Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.510

N/A

0.104DataRank · unranked

1 citations

Amy S. Clark, Christina Yau, Denise M. Wolf, L. J. van ‘t Veer, Emily Douglas +10 more

Distribution of breast cancer molecular subtypes within receptor classifications: Lessons from the I-SPY2 Trial and FLEX Registry.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.592

N/A

0.104DataRank · unranked

1 citations

Paige Warner, Robert Hiatt, Scarlett Lin Gomez, L. J. van ‘t Veer, Allison Stover Fiscalini +11 more

Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.514

N/A

0.104DataRank · unranked

1 citations

Denise M. Wolf, Christina Yau, Emanuel F. Petricoin, Paula R. Pohlmann, Lajos Pusztai +10 more

CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial

npj Breast Cancer(2025)10.1038/s41523-025-00830-y

N/A

0.104DataRank · unranked

1 citations

Karen S. Flatten, Taylor M. Weiskittel, Annapoorna Venkatachalam, Annabella R. Strathman, Olivia K. Rossman +17 more

Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial

Annals of Surgical Oncology(2025)10.1245/s10434-025-17864-y

N/A

0.104DataRank · unranked

1 citations

Katrina Dimitroff, Judy C. Boughey, Laura J. Esserman, Christina Yau, Julia Tchou +34 more

Data from Targeting HER-2/neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion

(2023)10.1158/0008-5472.c.6496416

N/A

0DataRank · unranked

0 citations

Gary K. Koski, Ursula Koldovsky, Shuwen Xu, Peter A. Cohen, Rosemarie Mick +16 more

The effects of exercise and diet on oxidative stress and telomere length in breast cancer survivors

Breast Cancer Research and Treatment(2023)10.1007/s10549-023-06868-5

N/A

0DataRank · unranked

12 citations

Kathleen M. Sturgeon, David B. Sarwer, Andrea B. Troxel, Angela DeMichele, Crystal S. Denlinger +2 more

The effects of exercise and diet on sex steroids in breast cancer survivors

Endocrine Related Cancer(2022)10.1530/erc-22-0084

N/A

0DataRank · unranked

7 citations

Kathleen M. Sturgeon, David B. Sarwer, Andrea B. Troxel, Angela DeMichele, Crystal S. Denlinger +2 more

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

Annals of Oncology(2022)10.1016/j.annonc.2022.04.072

N/A

0DataRank · unranked

21 citations

Anna Mrukwa, Christina Yau, Denise M. Wolf, Y.-Y. Chen, Ronald Balassanian +26 more

Retrospective cohort analysis of prescription patterns of cancer medications during periods of drug stockouts in Botswana

BMJ Open(2021)10.1136/bmjopen-2021-049574

N/A

0DataRank · unranked

6 citations

Surbhi Grover, Warren B. Bilker, Dipho I. Setlhako, Tlotlo Ralefala, Patrick Manshimba +5 more

Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab

JACC Basic to Translational Science(2021)10.1016/j.jacbts.2021.10.010

N/A

0DataRank · unranked

14 citations

Biniyam G. Demissei, Amanda M. Smith, Priya Brahmbhatt, Jessica Wang, Amy S. Clark +10 more

Effects of systemic inflammation on relapse in early breast cancer

npj Breast Cancer(2021)10.1038/s41523-020-00212-6

N/A

0DataRank · unranked

37 citations

Lisa N. Bottalico, Clementina Mesaros, Ian A. Blair, Patricia Tsao, Jennifer M. Rosado +6 more

A randomized trial of exercise and diet on health‐related quality of life in survivors of breast cancer with overweight or obesity

Cancer(2021)10.1002/cncr.33752

N/A

0DataRank · unranked

32 citations

David B. Sarwer, Andrea B. Troxel, Kathleen M. Sturgeon, Angela DeMichele, Crystal S. Denlinger +2 more

Randomized trial of web-based genetic education versus usual care in advanced cancer patients undergoing tumor genetic testing: Results from the ECOG-ACRIN NCI Community Oncology Research Program (NCORP; EAQ152) COMET trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.2008

N/A

0DataRank · unranked

0 citations

Ju‐Whei Lee, Jill B. Gaieski, Shuli Li, Ilana F. Gareen, Keith T. Flaherty +15 more

Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors

Journal of Obstetrics and Gynaecology(2020)10.1080/01443615.2020.1754369

N/A

0DataRank · unranked

7 citations

Michael Vance Homer, Loki Natarajan, Carolyn Haunschild, Karine Chung, Jun J. Mao +3 more

Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancer

Research Square(2025)10.21203/rs.3.rs-6926989/v1

N/A

0DataRank · unranked

2 citations

Xiaopeng Sun, Ann Hanna, Andres A. Ocampo, Brandie C. Taylor, James R. Marshall +14 more

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.03.30.534178

N/A

0DataRank · unranked

0 citations

Amrita Basu, Christina Yau, Denise M. Wolf, Hani Goodarzi, Sourav Bandyopadhyay +11 more

Data from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

(2023)10.1158/1078-0432.c.6532368.v1

N/A

0DataRank · unranked

0 citations

Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan +15 more

Angela DeMichele

Indexed papers

Top data-sharing exemplar

Papers